000			03245nam a22003855i 4500
999			_c100933 _d100933
001			100933
003			ESmaUEC
005			20230102113018.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			180628s2018 si | s |||| 0|eng d
020			_a9789811086847
024	7		_a10.1007/978-981-10-8684-7 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aQH506
245	1	0	_aObesity, Fatty Liver and Liver Cancer _cedited by Jun Yu.
264		1	_aSingapore _bSpringer International Publishing _c2018
300			_a1 recurso en línea (XII, 157 páginas 24 ilustraciones,23 ilustraciones a color)
336			_aTexto _btxt _2rdacontent
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aAdvances in Experimental Medicine and Biology, _x0065-2598 _v1061
490	0		_aBiomedical and Life Sciences (Springer-11642)
505	0		_aChapter 1. Introduction -- Chapter 2. Epidemiology and etiology of NAFLD and associated HCC -- Chapter 3. Pathogenesis of NASH: How metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease -- Chapter 4. Chemokines and Chemokine Receptors in the Development of NAFLD -- Chapter 5. NAFLD related-HCC: the relationship with metabolic disorders -- Chapter 6. Hepatocellular carcinoma in obesity: Finding a needle in the haystack? -- Chapter 7. Dysregulated epigenetic modifications in the pathogenesis of NAFLD-HCC -- Chapter 8. The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease -- Chapter 9. Microbiota, obesity and NAFLD -- Chapter 10. Autophagy, NAFLD and NAFLD-related HCC -- Chapter 11. Animal models of non-alcoholic fatty liver diseases and its associated liver cancer -- Chapter 12. Current prevention and treatment options for NAFLD.
520	3		_aThis volume covers a state-of-the-art illustration of recent discoveries concerning obesity-related fatty liver diseases and liver cancer. The contents are extensive and comprehensive. It brings important topics in the field all together under one umbrella, from epidemiology and etiology, molecular pathogenesis, cellular biology, epigenetics, immunology, microbiology, animal models to therapeutic approaches and treatments. All the book contributors are leading experts in the field. It will appeal to researchers, clinicians and graduate students in obesity, fatty liver diseases, GI/Liver cancer field. It may also yield benefits for pharmaceutical companies with regard to drug discovery.
988			_aEBSPRINGER_2018
650		7	_2embne _aBiología molecular _9139103
700	1		_aYu, Jun. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/n85091550
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _9106996
776	0	8	_iEdición impresa: _z9789811086830
776	0	8	_iEdición impresa: _z9789811086854
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-10-8684-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE